LTRN
Lantern Pharma Inc. (LTRN) Management Analysis (2026)
Overall Score
Execution Profitability
TTM profitability remains deeply negative, with ROA at -2.17%, ROE at -4.56%, and ROIC at -3.58%.
Operating margins are still effectively zero, indicating no meaningful earnings power in the current run-rate.
Cash generation remains negative, with free cash flow yield at -0.57% and operating cash flow yield at -1.28%.
Balance Sheet Liquidity
Liquidity is adequate, with a current ratio of 1.96x and a cash ratio of 1.54x.
Debt appears minimal relative to market value, with debt-to-assets at 0.46% and debt-to-market-cap at 0.16%.
However, negative book value and negative net current asset value indicate a weak asset base despite near-term liquidity.
Capital Allocation
There is no evidence of shareholder returns, as dividend yield and payout ratio are both 0%.
Negative free cash flow and negative operating cash flow limit flexibility for buybacks, acquisitions, or reinvestment.
With returns on capital still negative, capital deployment has not yet translated into value creation.
Leadership Governance
No recent news or disclosed management actions indicate a change in strategic direction this month.
The operating profile remains highly challenged, so management credibility still depends on demonstrating sustained improvement in profitability and cash flow.
Absent new guidance or execution updates, the leadership assessment remains constrained by weak financial outcomes.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

